Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 701–800 of 1,000
Takagi, H., & Umemoto, T. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.079 · Cited by 16
“Indeed, the value of rosuvastatin in treatment of HF has been recently questioned, due to the lack of observed clinical benefits in well-treated patients with HF in 2 large (>4000 patients) randomized placebo-controlled multicenter trials (Controlled Rosuvastatin Multinational Trial in Heart Failure [CORONA] [22] and…”
BackgroundMischie, A. N., Chioncel, V., Droc, I., & Sinescu, C. J. (2012) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12019 · Cited by 16
“3% was found in the placebo group [5].”
BackgroundObservational Studies of Statins in Heart Failure with Preserved Systolic Function
Fukuta, H., & Little, W. C. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.01.005 · Cited by 17
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Strandberg, T. E. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328338bc2d · Cited by 16
Bonsu, K. O., Owusu, I. K., Buabeng, K. O., Reidpath, D. D., & Kadirvelu, A. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s106065 · Cited by 16
Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials
Rahal, A. J., El‐Mallah, A., Poushuju, R. J., & Itani, R. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.10.16078 · Cited by 18
Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation
Vest, A. R., Kennel, P. J., Maldonado, D. A., Young, J. B., Mountis, M., Naka, Y., Colombo, P. C., MANCINI, D. M., Starling, R. C., & Schulze, P. C. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002881 · Cited by 16
Krittanawong, C., & Kukin, M. L. (2018) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-018-0623-1 · Cited by 17
Soluble ST2 and Soluble Markers of Fibrosis: Emerging Roles for Prognosis and Guiding Therapy
Sharim, J., & Daniels, L. B. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01288-z · Cited by 17
Biomarker Development in Cardiology: Reviewing the Past to Inform the Future
Kott, K. A., Bishop, M. D., Yang, C., Plasto, T. M., Cheng, D. C., Kaplan, A. I., Cullen, L., Celermajer, D. S., Meikle, P. J., Vernon, S. T., et al. (2022) · Cells · doi:10.3390/cells11030588 · Cited by 23
Sehra, D., Sehra, S., & Sehra, S. T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1338269 · Cited by 19
Statin treatment and increased diabetes risk. Possible mechanisms
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.12.001 · Cited by 19
Zhang, X., Lan, R., Zhang, X., Xu, W., Wang, L., Kang, L., & Xu, B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012428 · Cited by 15
Sex and Gender-Related Issues in Heart Failure
Romiti, G. F., Recchia, F., Zito, A., Visioli, G., Basili, S., & Raparelli, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.005 · Cited by 16
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109788340712 · Cited by 16
“ESRD and heart failure) despite a significant fall in LDL-C levels [28, 29].”
BackgroundPacker, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1183 · Cited by 18
Boussageon, R., Blanchard, C., Charuel, É., Ménini, T., Pereira, B., Naudet, F., Kassaï, B., Gueyffier, F., Cucherat, M., & Vaillant-Roussel, H. (2022) · Therapies · doi:10.1016/j.therap.2022.10.008 · Cited by 22
Gouveia, R., MADUREIRA, S., Elias, C., Neves, A., Soares, P. R., Carreira, M., Pereira, J., Ribeiro, A., Amorim, M. J., Almeida, J., et al. (2023) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2023.200197 · Cited by 19
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study
Chitnis, A. S., Aparasu, R. R., Chen, H., Kunik, M. E., Schulz, P. E., & Johnson, M. L. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0295-4 · Cited by 15
Comparative effects of statins on murine cardiac gene expression profiles in normal mice
Kumazaki, M., Ando, H., Ushijima, K., & Fujimura, A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.022 · Cited by 15
The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia
Barnett, J., Viljoen, A., & Wierzbicki, A. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0391-1 · Cited by 13
de Lorgeril, M., & Rabaeus, M. (2016) · Journal of Controversies in Biomedical Research · doi:10.15586/jcbmr.2015.11 · Cited by 18
“various degrees of cardiac dysfunction – and at high risk of AMI recurrence and cardiac death (52);”
BackgroundMethodResultInfluentialPharmacological interventions for heart failure in people with chronic kidney disease
Ravani, P., Quinn, R. R., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466 · Cited by 16
Adhyaru, B. B., & Jacobson, T. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0666-x · Cited by 16
Aboumsallem, J. P., Muthuramu, I., Mishra, M., & Geest, B. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092222 · Cited by 16
“In clear contrast, statins do not appear to result in major beneficial effects in patients with established heart failure as has been demonstrated in the CORONA and GISSI-HF trials [46,47].”
ResultGama, F. F., Ferreira, J., Carmo, J., Costa, F. M., Carvalho, S., Carmo, P., Cavaco, D., Morgado, F. B., Adragão, P., & Mendes, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015177 · Cited by 14
Hit or miss: the new cholesterol targets
DuBroff, R. J., Malhotra, A., & de Lorgeril, M. (2020) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111413 · Cited by 17
Vasques‐Nóvoa, F., Ferreira, J. P., Marques, P. S., Neves, J. S., Vale, C., Ribeirinho-Soares, P., Marques, J. A. D. C., Martins, S., Guimarães, J. T., Barros, A. S., et al. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156053 · Cited by 15
Effects of statin and lipoprotein metabolism in heart failure
Miura, S., & Saku, K. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2010.02.003 · Cited by 15
Moss, A. S., Dimitropoulos, G., Connolly, D. L., & Lip, G. Y. H. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1350647 · Cited by 15
Cholesterol-Lowering Gene Therapy Counteracts the Development of Non-ischemic Cardiomyopathy in Mice
Muthuramu, I., Amin, R., Postnov, A. A., Mishra, M., Aboumsallem, J. P., Dresselaers, T., Himmelreich, U., Veldhoven, P. P. V., Gheysens, O. S., Jacobs, F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.017 · Cited by 16
Statins: Rationale, Mode of Action, and Side Effects
Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Τσούπρας, Α., Kavanagh, E. P., & Hynes, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00006-9 · Cited by 25
Chen, Y., He, X., Meng, H., Zhao, Q., Zhen, Y., Tian, L., Wang, L., Ji, L., Ma, G., Tian, Y., et al. (2014) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2014.03.011 · Cited by 20
Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo
Pfeffer, M. A. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.01.003 · Cited by 14
Guyton, J. R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c1f16 · Cited by 17
Watanabe, S., Yoshihisa, A., Kanno, Y., Takiguchi, M., Yokokawa, T., Sato, A., Miura, S., Shimizu, T., Abe, S., Sato, T., et al. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.04.017 · Cited by 17
Holme, I., Strandberg, T. E., Færgeman, O., Kastelein, J. J. P., OLSSON, A. G., Tikkanen, M. J., Larsen, M. L., Lindahl, C., & Pedersen, T. R. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.023 · Cited by 15
Packer, M. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004551 · Cited by 16
Cardiometabolic Dysregulation and Heart Failure
Ashfield, S., & Ojha, U. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38504 · Cited by 15
Chunawala, Z. S., Qamar, A., Arora, S., Pandey, A., Fudim, M., Vaduganathan, M., Mentz, R. J., Bhatt, D. L., & Caughey, M. C. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2617 · Cited by 14
Initiation of Statins for Primary Prevention in Heart Failure With Preserved Ejection Fraction
Orkaby, A. R., Goyal, P., CHAREST, B. R., Qazi, S., Sheikh, S. M., Shah, S. J., Gaziano, J. M., Djoussé, L., GAGNON, D. R., & Joseph, J. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100869 · Cited by 22
Barrios, V., Escobar, C., Murga, N., & Quijano, J. J. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.01.003 · Cited by 15
“There is a growing body of evidence from clinical trials indicating that risk factor modification in older adults reduces coronaryheart disease risk as effectively as it does inmiddle-aged subjects [17,18,26,27].”
BackgroundSelf-citationEffect of Rosuvastatin on Fatigue in Patients With Heart Failure
Moreno, A. C. P., Jhund, P. S., Preiss, D., KJEKSHUS, J. K., & McMurray, J. J. V. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.004 · Cited by 14
Self-citationStatin Use After Acute Myocardial Infarction by Patient Complexity: Are the Rates Right?
Brooks, J. M., Cook, E. A., Chapman, C. G., Schroeder, M. C., Chrischilles, E. A., Schneider, K. M., Kulchaitanaroaj, P., & Robinson, J. G. (2015) · Medical Care · doi:10.1097/mlr.0000000000000322 · Cited by 16
Chronic heart failure: epidemiology, investigation and management
Gardner, R. S., & McDonagh, T. A. (2014) · Medicine · doi:10.1016/j.mpmed.2014.07.008 · Cited by 15
Effects of Statins on Cardiorenal Syndrome
Yagi, S., Aihara, K., Ikeda, Y., Akaike, M., Sata, M., & Matsumoto, T. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/162545 · Cited by 14
Hoang, T., & Kim, J. (2020) · Nutrients · doi:10.3390/nu12082218 · Cited by 16
Straw, S., McGinlay, M., Relton, S. D., Koshy, A. O., Gierula, J., Paton, M. F., Drozd, M., Lowry, J. E., Cole, C. A., Cubbon, R. M., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12978 · Cited by 14
“001 CRT‐P [n (%)] 452 (25) 103 (22) 206 (27) 118 (27) 25 (23) 0.”
Camafort, M., Jhund, P. S., Formiga, F., Castro, A., Arévalo‐Lorido, J. C., Sobrino-Martínez, J., Manzano, L., Díez‐Manglano, J., Aramburu, Ó., Pérez‐Barquero, M. M., et al. (2021) · Revista Clínica Española · doi:10.1016/j.rce.2020.11.010 · Cited by 14
Hatamizadeh, P. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.05.001 · Cited by 15
Lewinter, C., Bland, J. M., Crouch, S., Cleland, J. G. F., Doherty, P., LeWinter, M. M., Køber, L., Hall, A. S., & Gale, C. P. (2013) · European Journal of Heart Failure · doi:10.1002/ejhf.40 · Cited by 15
Self-citationMorimoto, T., Katanasaka, Y., Sunagawa, Y., Hirano, S., Miyazaki, Y., Funamoto, M., Hojo, Y., Suzuki, H., Morimoto, E., Ueno, M., et al. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00126 · Cited by 14
Ueland, T., Aukrust, P., Nymo, S. H., KJEKSHUS, J. K., McMurray, J. J. V., Wikstrand, J., Block, D., Zaugg, C. E., & Gullestad, L. L. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.10.016 · Cited by 16
Self-citationStatin Therapy in Heart Failure: For Good, for Bad, or Indifferent?
Gennaro, L. D., Brunetti, N. D., Correale, M., Buquicchio, F., Caldarola, P., & Biase, M. D. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0377-x · Cited by 14
“fraction (LVEF) and symptoms of HF [10–14], the results of two recent large RCTs [15,16] have challenged these findings.”
BackgroundInfluentialStrategies to Prevent Postdischarge Adverse Events Among Hospitalized Patients with Heart Failure
Psotka, M. A., & Teerlink, J. R. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.04.005 · Cited by 14
Mortality and morbidity of newly diagnosed heart failure treated with statins
Gomez-Soto, F. M., Romero, S. P., Bernal, J. A., Escobar, M. A., Puerto, J. L., Andrey, J. L., Ruiz, P., & Gomez, F. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.042 · Cited by 14
Changes in Cholesterol-Lowering Medications Use Over a Decade in Community-Dwelling Older Adults
Lo-Ciganic, W.-H., Boudreau, R. M., Gray, S. L., Zgibor, J. C., Donohue, J. M., Perera, S., Newman, A. B., Simonsick, E. M., Bauer, D. C., Satterfield, S., et al. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1s050 · Cited by 16
Lin, Z., Wang, C., Shen, L., Hsiao, F., & Wu, F. L. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.12.006 · Cited by 19
Said, N. O. E., Wakeel, L. M. E., Khorshid, H. M., Darweesh, E. A. G., & Ahmed, M. A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14695 · Cited by 14
Coletta, A. P., Cullington, D., Clark, A. L., & Cleland, J. G. F. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.10.002 · Cited by 14
Self-citationO’Keefe, J. H., Carter, M. D., Lavie, C. J., & Bell, D. S. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2010 · Cited by 19
The endotoxin-lipoprotein hypothesis – an update
Sandek, A., Utchill, S., & Rauchhaus, M. (2008) · Cited by 15
Laufs, U., NEF, H. M., Möllmann, H., Custodis, F., & Böhm, M. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-008-0625-1 · Cited by 14
Self-citationIncreasing Post-Myocardial Infarction Heart Failure Incidence in Elderly Patients
Liang, C., & Delehanty, J. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.026 · Cited by 14
Plasma sodium and mortality risk in patients with myocardial infarction and a low LVEF
Schou, M., Valeur, N., Torp-Pedersen, C. T., Gustafsson, F., & Køber, L. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02532.x · Cited by 13
Delayed and Indirect Effects of Antiarrhythmic Drugs in Reducing Sudden Cardiac Death
Malhotra, S., & Das, M. K. (2011) · Future Cardiology · doi:10.2217/fca.11.3 · Cited by 14
Novel strategies for managing dyslipidemia: treatment beyond statins
Ling, H., Burns, T. L., & Hilleman, D. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2612 · Cited by 10
Atrial fibrillation in heart failure: drug therapies for rate and rhythm control
Tadros, R., Khairy, P., Rouleau, J. L., Talajic, M. R., Guerra, P. G., & Roy, D. (2013) · Heart Failure Reviews · doi:10.1007/s10741-013-9395-6 · Cited by 13
Management of Comorbid Conditions in Heart Failure
Nagarajan, V., & Tang, W. H. W. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.006 · Cited by 16
Statin therapy across the lifespan: evidence in major age groups
Stone, N. J., Turin, A., Spitz, J. A., Valle, C. W., & Kazmi, S. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1128825 · Cited by 14
Statins and peripheral arterial disease.
Markel, A. (2015) · PubMed · Cited by 15
Corrao, G., Compagnoni, M. M., Franchi, M., Cantarutti, A., Pugni, P., Merlino, L. G., Catapano, A. L., & Mancia, G. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.09.023 · Cited by 15
Prediction of sudden death in elderly patients with heart failure.
Ayesta, A., Martínez-Sellés, H., de Luna, A. B., & Martínez‐Sellés, M. (2018) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2018.02.008 · Cited by 17
Drug therapies in chronic heart failure: a focus on reduced ejection fraction
Bolam, H., Morton, G., & Kalra, P. R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-2-138 · Cited by 15
Cardioprotective cytokine interleukin‐33 is up‐regulated by statins in human cardiac tissue
Pentz, R., Kaun, C., Thaler, B., Stojković, S., Lenz, M. W., Krychtiuk, K. A., Zuckermann, A. O., Huber, K., Wojta, J., Hohensinner, P. J., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13891 · Cited by 14
“statins in patients with HF.(40,41) On the other hand, the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an”
BackgroundInfluentialStatin therapy is associated with improved survival in patients with ventricular tachyarrhythmias
Rusnak, J., Behnes, M., Schupp, T., Lang, S., Reiser, L., Taton, G., Bollow, A., Reichelt, T., Ellguth, D., Engelke, N., et al. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1011-x · Cited by 13
Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction
Kim, E.-S., Youn, J., & Baek, S. H. (2020) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2020.2.e17 · Cited by 16
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_6 · Cited by 17
Thomopoulos, C., Skalis, G., Michalopoulou, H., Tsioufis, C. P., & Makris, T. (2015) · Clinical Cardiology · doi:10.1002/clc.22441 · Cited by 14
Lee, H., Cho, H.-J., Kim, H.-Y., Jeon, H.-K., Shin, J. H., Kang, S.-M., & Baek, S. H. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.6.754 · Cited by 15
Role of Drug Therapy for Sustained Ventricular Tachyarrhythmias
Mitchell, L. B. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.03.004 · Cited by 13
Daimon, M., Oizumi, T., Kameda, W., Matsui, J., Murakami, H., Ueno, Y., Kubota, I., Yamashita, H., Kayama, T., & Kato, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.29181 · Cited by 13
Cardiovascular Aspects of Kidney Disease
Wheeler, D. C., Haynes, R., Landray, M., & Baigent, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10055-7 · Cited by 14
Parida, S., Swain, T. R., Routray, S. N., & Maiti, R. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/23741.9427 · Cited by 16
Siddiqui, A. J., & Holzmann, M. J. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.019 · Cited by 18
Roy, D., Mahapatra, T., Manna, K., Kar, A., Rana, M. S., Roy, A., Bose, P. K., Banerjee, B., Paul, S., & Chakraborty, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233230 · Cited by 18
Benefits of statins beyond lipid lowering
Merx, M. W., & Weber, C. (2008) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2008.10.001 · Cited by 13
on behalf of the DAPPER investigators and study coordinators, Yoshihara, F., Imazu, M., Hamasaki, T., Anzai, T., Yasuda, S., Ito, S., Yamamoto, H., Hashimura, K., Yasumura, Y., et al. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6782-1 · Cited by 12
“However, further efforts are needed for the effective treatment for CHF because the number of CHF patients has continued to rise with increase in the prevalence of lifestyle-related diseases such as diabetes [3], hypertension [4], and dyslipidemia [5].”
BackgroundHerzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien
Hoppe, U. C., & Erdmann, E. (2010) · Herz · doi:10.1007/s00059-010-3396-1 · Cited by 14
Anticoagulants, Antiplatelets, and Statins in Heart Failure
Farmakis, D. T., Filippatos, G. S., Lainščak, M., Parissis, J., Anker, S. D., & Kremastinos, D. T. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.10.001 · Cited by 13
Observational Studies of Statins in Systolic Heart Failure
Levy, W. C. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2008.01.006 · Cited by 14
Statins: established indications and controversial subgroups
Jukema, J. W., & Bergheanu, S. C. (2008) · Heart · doi:10.1136/hrt.2008.151506 · Cited by 13
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 13
yuzefpolskaya, M., Bohn, B., Ladanyi, A., Khoruts, A., Colombo, P. C., & Demmer, R. T. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.12.009 · Cited by 13
Lipoprotein(a) and heart failure: a systematic review
Masson, W. M., Barbagelata, L., Cobo, A. L., Corral, P., & Nogueira, J. P. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10333-2 · Cited by 14
Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect
Majid, A., Hassan, F. O., Hoque, M. M., Gbadegoye, J. O., & Lebeche, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070313 · Cited by 16
The reversal of cardiology practices: interventions that were tried in vain.
Prasad, V. K., & Cifu, A. S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-3652.2013.10.05 · Cited by 15
Mizuno, K., Nakaya, N., Teramoto, T., Yokoyama, S., Ohashi, Y., Ueki, A., Takahashi, S., Kubota, Y., & Nakamura, H. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9183 · Cited by 14
Dobre, D., Rossignol, P., Murín, J., Parkhomenko, A. N., Lamiral, Z., Krum, H., van Veldhuisen, D. J., Pitt, B., & Zannad, F. M. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs128 · Cited by 13
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.